Literature DB >> 2940299

Activated suppressor cell dysfunction in progressive multiple sclerosis.

J P Antel, M B Bania, A Reder, N Cashman.   

Abstract

Concanavalin A (Con A)-induced suppressor activity has previously been shown to be reduced in multiple sclerosis (MS) patients with active clinical disease. In this study, we demonstrate that OKT3, as well as Con A induced suppressor activity mediated by unfractionated peripheral blood mononuclear cells is reduced in patients with the progressive form of MS. By performing reconstitution experiments involving E+, T4+, or T8+ cells derived from either MS patients or controls, and normal allogeneic macrophages or E- cells, we sought to define the cellular basis for this suppressor defect. In both MS and control groups, E+ cells were required to obtain measurable levels of suppression. Suppressor levels induced by Con A-activated cultures containing E+ cells from MS patients were lower than those induced by those containing control donor E+ cells. Suppression mediated by T8+ cells from MS patients was also lower than for controls. In the control group, suppression mediated by T8+ cells exceeded that mediated by T4+ cells; such differences were not apparent in the MS group. These results suggest that although Con A-induced suppression can be mediated by a number of T and non-T cell subsets, the functional suppressor defect measured in the MS population does involve the T8+ cell subset.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2940299

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  17 in total

1.  Regulation of T-cell activation in the lung: isolated lung T cells exhibit surface phenotypic characteristics of recent activation including down-modulated T-cell receptors, but are locked into the G0/G1 phase of the cell cycle.

Authors:  D Strickland; U R Kees; P G Holt
Journal:  Immunology       Date:  1996-02       Impact factor: 7.397

Review 2.  Mechanisms of action of interferon-beta in multiple sclerosis.

Authors:  B G Arnason; A Dayal; Z X Qu; M A Jensen; K Genç; A T Reder
Journal:  Springer Semin Immunopathol       Date:  1996

3.  Dual labelling of circulating CD8 cells in patients with multiple sclerosis.

Authors:  P J Hughes; P F Kirk; D A Compston
Journal:  J Neurol Neurosurg Psychiatry       Date:  1989-01       Impact factor: 10.154

4.  Peripheral blood lymphocyte phenotype and function in multiple sclerosis.

Authors:  P J Hughes; D A Compston
Journal:  J Neurol Neurosurg Psychiatry       Date:  1988-09       Impact factor: 10.154

Review 5.  Multiple Sclerosis and T Lymphocytes: An Entangled Story.

Authors:  Laurine Legroux; Nathalie Arbour
Journal:  J Neuroimmune Pharmacol       Date:  2015-05-07       Impact factor: 4.147

6.  Neuroantigen-specific CD8+ regulatory T-cell function is deficient during acute exacerbation of multiple sclerosis.

Authors:  Ethan J Baughman; Jason P Mendoza; Sterling B Ortega; Chris L Ayers; Benjamin M Greenberg; Elliot M Frohman; Nitin J Karandikar
Journal:  J Autoimmun       Date:  2011-01-22       Impact factor: 7.094

7.  Circulating CD3+ CD4+ CD8+ T lymphocytes in multiple sclerosis.

Authors:  F E Munschauer; C Stewart; L Jacobs; S Kaba; Z Ghorishi; S J Greenberg; D Cookfair
Journal:  J Clin Immunol       Date:  1993-03       Impact factor: 8.317

8.  Novel CD8+ Treg suppress EAE by TGF-beta- and IFN-gamma-dependent mechanisms.

Authors:  Mei-Ling Chen; Bo-Shiun Yan; Deneen Kozoriz; Howard L Weiner
Journal:  Eur J Immunol       Date:  2009-12       Impact factor: 5.532

9.  Lymphocyte activating factor activity in the serum and cerebrospinal fluid of patients with multiple sclerosis.

Authors:  D Donati; P Annunziata; G C Guazzi; D Boraschi; A Tagliabue
Journal:  Ital J Neurol Sci       Date:  1990-02

10.  Inhibition of T cell responses by activated human CD8+ T cells is mediated by interferon-gamma and is defective in chronic progressive multiple sclerosis.

Authors:  K E Balashov; S J Khoury; D A Hafler; H L Weiner
Journal:  J Clin Invest       Date:  1995-06       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.